Metabolic Disorders

An average overall price reduction of 48% for insulin products in China is expected to generate annual savings of $1.4bn through 2023, but multinational pharma firms will be hit hard by the bidding process.

The value-based procurement scheme in China is about to be implemented on insulin products and while most of Novo Nordisk's therapies were included in the tender, price cuts are going to impact global sales growth by 3% next year.

The Denmark-headquartered major is impressed with what it has seen in Dicerna in the two years since the companies teamed up and is paying an 80% premium to get hold of the US firm's RNAi technology platforms.

Wegovy is set to join Saxenda as the company’s second EU approved drug for obesity, helping it corner the region’s weight-management market, once the company gets its supply back on track.

Novo Nordisk’s obesity product sales have soared against the odds as supply chain issues for recently approved Wegovy continued.

Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.   

In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are nine new products for endocrine and metabolic disorders that could make their debuts next year.

CEO David Meeker spoke with Scrip about how the company is targeting its drug, Imcivree, across potentially dozens of rare genetic diseases of obesity.

France’s Provepharm Life Solutions, which finds new uses for known mature molecules, in particular antidotes and surgical dyes, by improving their efficacy and maximizing their therapeutic potential, has fresh funds to expand its portfolio.

Provention has been working hard collecting necessary data for a potential BLA resubmission for teplizumab in patients at risk of developing type 1 diabetes after receiving a complete response letter in July. Hopes rest on a Type A meeting with the FDA in Q4.

The failed muscle-adding antibody could offer a superior profile in obesity by reducing body fat composition while increasing lean mass, the firm believes.

Deal Snapshot: VectivBio is expanding its existing focus on rare diseases into inherited metabolic disorders, which affect about one in 800 live births and cause significant mortality in infants and young people.